Allergy Technologies' chief executive buys 50,000 shares
27th Jul 2015 16:58
(ShareCast News) - The chief executive of Allergy Therapeutics bought new shares in the company few days after releasing a positive trading update. Manuel Llobet purchased 50,000 shares for an individual price of 24.45p, spending a total of £12,225. After the transaction, Llobet holds 3.175m shares
Read moreAllergy Therapeutics dust mite study yields positive results
6th Jul 2015 07:43
Pharmaceutical group Allergy Therapeutics has announced positive results from a clinical study for the treatment of house dust mite allergy. Results of the observational one-year follow-up study of Acarovac Plus showed that there were no adverse effects to the tolerability of the product, while ther
Read moreAllergy Therapeutics buys Alerpharma for 3.8m euros
5th Jun 2015 11:14
Specialty pharmaceutical company Allergy Therapeutics said on Friday that it has agreed to buy Alerpharma SA for an initial consideration of €3.8m. Alerpharma wholly owns the Spanish-based allergy immunotherapy company Instituto de Immunologia y Alergia (Inmunal),which is a spin-out of biopharmaceut
Read moreTuesday broker round-up UPDATE
1st Apr 2014 09:39
African Barrick Gold: Deutsche Bank raises target price from 240p to 310p and keeps a hold recommendation. African Minerals: Deutsche Bank lowers target price from 399p to 382p, while its buy recommendation is kept. Allergy Therapeutics: Panmure Gordon ups target price from 16p to 25p and retains
Read moreAllergy Therapeutics reports rise in first half profits and revenue
24th Mar 2014 13:48
Allergy Therapeutics reported an 11 per cent rise in gross profit to 20.7m pounds in the first half as costs were reduced. The cost of goods fell to £6.4m in the last six months of 2013, compared to £7m, following a number of cost cutting measures. Gross revenue, excluding the German rebate and
Read moreAllergy Therapeutics gets green light for hay fever study in Canada
19th Feb 2014 13:21
Speciality pharmaceuticals firm Allergy Therapeutics has received the approval from the Canadian health regulators to submit a full clinical trial application for a new study of its hay fever vaccine. Following on from successful discussions held with the US Food and Drug Administration previously,
Read moreAllergy Therapeutics boosts sales, gains market share
20th Nov 2013 07:38
Allergy vaccine developer Allergy Therapeutics reported higher sales and revenue since July and said it was gaining share in all its main markets. The group said net revenues rose 16% in the first four months of this financial year against the same period last year while gross sales at constant cur
Read moreMonday broker round-up
16th Sep 2013 12:13
AEC Education: WH Ireland places both its target price (prev.: 11p) and its recommendation under review. Aggreko: Citi reduces target price from 2100p to 2000p leaving its buy recommendation unaltered. Allergy Therapeutics: Panmure Gordon lowers target price from 18p to 16p, while keeping its buy
Read moreAllergy Therapeutics ends contract with Lincoln Medical
27th Dec 2012 14:29
Allergy Therapeutics has terminated its agreement with Lincoln Medical for the distribution rights of Anapen in a number of countries, following a recall of the drug in the UK. The pharmaceutical company said Lincoln Medical undertook a voluntary recall of all unexpired units of Apapen, an adrenali
Read moreChamberlin Chairman invests 75k
10th Dec 2012 16:25
Castings and engineering group Chamberlin announced on Monday that its Chairman has topped up his stake in the company twice over the couple of weeks. Keith Butler-Wheelhouse acquired a total of 44,500 Chamberlin ordinary shares through his family trust, BW Family Limited (BWFL), representing 0.56%
Read moreShanks Chairman buys shares as profits fall
9th Nov 2012 16:30
The Chairman of Shanks Group, the FTSE 250 waste management firm, has bought 60,000 shares in the firm following the company's announcement that half year profits fell by 29 per cent. Chairman Adrian Auer purchased the shares at 82.93p each for a total of £49,758. On Thursday the company revealed
Read moreSmall caps round-up: Allergy, XCAP, Totally...
3rd Aug 2012 11:45
Allergy Therapeutics, a specialist pharmaceutical company focused on allergy vaccination, has welcomed the Food and Drugs Association's decision to lift the clinical hold on the company's grass pollen allergy vaccine clinical development programme, with immediate effect. Allergy has gained approval
Read moreAllergy gets FDA lift
26th Apr 2011 08:33
Shareholders in allergy vaccine developer Allergy Therapeutics were making hay Tuesday after the US Food and Drug Administration (FDA) signalled the imminent lifting of the clinical hold on three of the company's products. The FDA said the clinical hold on the Investigational New Drug applications
Read moreLondon close: Flat day for FTSE 100
28th Mar 2011 17:03
A second attempt to spring into life evaporated ahead of the close on Monday and the top share index finished just a few points higher. Worries that Japanese carmakers may have to suspend production at their plants in China following the earthquake disruption have sent copper prices lower. As a res
Read moreLondon afternoon: Shares mark time
28th Mar 2011 14:57
Footsie finished the morning clinging on to positive territory and not much changed over the lunch time trading session, with a mildly firmer start on Wall Street providing little additional impetus. Worries that Japanese carmakers may have to suspend production at their plants in China following t
Read more